FULC
Price
$10.94
Change
-$0.38 (-3.36%)
Updated
Nov 28 closing price
Capitalization
592.06M
89 days until earnings call
Intraday BUY SELL Signals
SLS
Price
$1.62
Change
+$0.16 (+10.96%)
Updated
Nov 28 closing price
Capitalization
230.76M
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FULC vs SLS

Header iconFULC vs SLS Comparison
Open Charts FULC vs SLSBanner chart's image
Fulcrum Therapeutics
Price$10.94
Change-$0.38 (-3.36%)
Volume$409.34K
Capitalization592.06M
SELLAS Life Sciences Group
Price$1.62
Change+$0.16 (+10.96%)
Volume$2.14M
Capitalization230.76M
FULC vs SLS Comparison Chart in %
FULC
Daily Signal:
Gain/Loss:
SLS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
FULC vs. SLS commentary
Nov 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FULC is a Hold and SLS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 30, 2025
Stock price -- (FULC: $10.94 vs. SLS: $1.62)
Brand notoriety: FULC and SLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FULC: 61% vs. SLS: 53%
Market capitalization -- FULC: $592.06M vs. SLS: $230.76M
FULC [@Biotechnology] is valued at $592.06M. SLS’s [@Biotechnology] market capitalization is $230.76M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FULC’s FA Score shows that 1 FA rating(s) are green whileSLS’s FA Score has 0 green FA rating(s).

  • FULC’s FA Score: 1 green, 4 red.
  • SLS’s FA Score: 0 green, 5 red.
According to our system of comparison, FULC is a better buy in the long-term than SLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FULC’s TA Score shows that 6 TA indicator(s) are bullish while SLS’s TA Score has 5 bullish TA indicator(s).

  • FULC’s TA Score: 6 bullish, 4 bearish.
  • SLS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, FULC is a better buy in the short-term than SLS.

Price Growth

FULC (@Biotechnology) experienced а -3.10% price change this week, while SLS (@Biotechnology) price change was +5.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.92%. For the same industry, the average monthly price growth was +1.16%, and the average quarterly price growth was +72.91%.

Reported Earning Dates

FULC is expected to report earnings on Feb 26, 2026.

SLS is expected to report earnings on Mar 13, 2026.

Industries' Descriptions

@Biotechnology (+6.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FULC($592M) has a higher market cap than SLS($231M). FULC YTD gains are higher at: 132.766 vs. SLS (55.769). SLS has higher annual earnings (EBITDA): -27.18M vs. FULC (-80.09M). FULC has more cash in the bank: 201M vs. SLS (25.3M). SLS has less debt than FULC: SLS (737K) vs FULC (7.01M). FULC (0) and SLS (0) have equivalent revenues.
FULCSLSFULC / SLS
Capitalization592M231M256%
EBITDA-80.09M-27.18M295%
Gain YTD132.76655.769238%
P/E RatioN/AN/A-
Revenue00-
Total Cash201M25.3M794%
Total Debt7.01M737K951%
FUNDAMENTALS RATINGS
FULC vs SLS: Fundamental Ratings
FULC
SLS
OUTLOOK RATING
1..100
1859
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
39
Fair valued
PROFIT vs RISK RATING
1..100
93100
SMR RATING
1..100
9399
PRICE GROWTH RATING
1..100
3665
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (26) in the null industry is in the same range as SLS (39) in the Biotechnology industry. This means that FULC’s stock grew similarly to SLS’s over the last 12 months.

FULC's Profit vs Risk Rating (93) in the null industry is in the same range as SLS (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to SLS’s over the last 12 months.

FULC's SMR Rating (93) in the null industry is in the same range as SLS (99) in the Biotechnology industry. This means that FULC’s stock grew similarly to SLS’s over the last 12 months.

FULC's Price Growth Rating (36) in the null industry is in the same range as SLS (65) in the Biotechnology industry. This means that FULC’s stock grew similarly to SLS’s over the last 12 months.

FULC's P/E Growth Rating (100) in the null industry is in the same range as SLS (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to SLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FULCSLS
RSI
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 6 days ago
87%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 10 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
FULC
Daily Signal:
Gain/Loss:
SLS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CVQZX9.660.05
+0.52%
Columbia Disciplined Value Inst
MUESX37.840.17
+0.45%
MFS Blended Research Core Equity R2
RMATX12.06N/A
N/A
Russell Inv Multi-Asset Strat M
RYFAX90.29N/A
N/A
Rydex Financial Services H
PRPDX74.10N/A
N/A
Permanent Portfolio Permanent A

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with SLS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then SLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
-3.36%
SLS - FULC
48%
Loosely correlated
+10.96%
NUVB - FULC
46%
Loosely correlated
+0.25%
SLDB - FULC
42%
Loosely correlated
+1.31%
BEAM - FULC
42%
Loosely correlated
+1.20%
TRDA - FULC
42%
Loosely correlated
+1.88%
More